

Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study

Sarah L. Pett,^{1,2,3} Ken M. Kunisaki,^{4,5} Deborah Wentworth,⁶ Timothy J. Griffin,⁷ Ioannis Kalomenidis,⁸ Raquel Nabra,⁹ Rocio Montejano Sanchez,¹⁰ Shane W. Hodgson,⁴ Kiat Ruxrungtham,^{11,12} Dominic Dwyer,¹³ Richard T. Davey,¹⁴ and Chris H. Wendt^{4,5}; for the INSIGHT FLU003 Plus Study Group*

¹Medical Research Council Clinical Trials Unit (MRC CTU), Institute of Clinical Trials and Methodology, University College London, UK; ²Clinical Research Group, Infections and Population Health, UCL, London, UK; ³Kirby Institute, University of New South Wales, Kensington, Australia; ⁴Minneapolis VA Health Care System, Minneapolis, Minnesota; ⁵Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, ⁶Division of Biostatistics, and ⁷Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota; ⁸1st Department of Critical Care and Pulmonary Medicine, University of Athens School of Medicine, Evangelismos General Hospital, Athens, Greece; ⁹Cooper University Hospital, Division of Infectious Disease, Camden, New Jersey; ¹⁰Hospital La Paz, Madrid, Spain; ¹¹HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand; ¹²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; ¹³Institute of Clinical Pathology and Medical Research, Pathology West and NSW Health Pathology, Westmead Hospital and University of Sydney, Westmead, Australia; and ¹⁴National National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Background. Indoleamine-2,3-dioxygenase (IDO) mediated tryptophan (TRP) depletion has antimicrobial and immuno-regulatory effects. Increased kynurenine (KYN)-to-TRP (KT) ratios, reflecting increased IDO activity, have been associated with poorer outcomes from several infections.

Methods. We performed a case-control (1:2; age and sex matched) analysis of adults hospitalized with influenza A(H1N1)pdm09 with protocol-defined disease progression (died/transferred to ICU/mechanical ventilation) after enrollment (cases) or survived without progression (controls) over 60 days of follow-up. Conditional logistic regression was used to analyze the relationship between baseline KT ratio and other metabolites and disease progression.

Results. We included 32 cases and 64 controls with a median age of 52 years; 41% were female, and the median durations of influenza symptoms prior to hospitalization were 8 and 6 days for cases and controls, respectively ($P = .04$). Median baseline KT ratios were 2-fold higher in cases (0.24 mM/M; IQR, 0.13–0.40) than controls (0.12; IQR, 0.09–0.17; $P \leq .001$). When divided into tertiles, 59% of cases vs 20% of controls had KT ratios in the highest tertile (0.21–0.84 mM/M). When adjusted for symptom duration, the odds ratio for disease progression for those in the highest vs lowest tertiles of KT ratio was 9.94 (95% CI, 2.25–43.90).

Conclusions. High KT ratio was associated with poor outcome in adults hospitalized with influenza A(H1N1)pdm09. The clinical utility of this biomarker in this setting merits further exploration.

ClinicalTrials.gov Identifier. NCT01056185.

Keywords. influenza; indoleamine-2,3-dioxygenase; kynurenine; outcome; tryptophan.

L-tryptophan (TRP) is an essential amino acid for many life forms including humans. Tryptophan is also an essential amino acid for protein synthesis for some bacteria, many fungi, and possibly some viruses. It is also the precursor molecule for several important neurotransmitters, that is, serotonin and melatonin. The role

of tryptophan in the immune response to many pathogens (eg, fungi, tuberculosis, trypanosomiasis, chronic viral infections) is an area of increased interest [1–3]. There is also considerable interest in the central role of tryptophan in the immune response and/or surveillance of malignant cells/tumors, and inhibitors of tryptophan metabolism (indoleamine 2,3-dioxygenase [IDO] inhibitors) are being developed as adjunctive immunotherapeutics in the cancer setting [4].

With respect to the role in the immune response to some pathogens, tryptophan depletion through the catabolic enzyme, IDO, is thought to be a mechanism to “starve” pathogens of this essential amino acid, but in turn it is coupled with a damping down of the immune response, as downstream metabolites of tryptophan affect the host immune response as well. There appear to be 3 tryptophan-catabolizing enzymes [5], of which IDO1 appears to be most important in the immune response to pathogens. IDO1 catabolizes TRP to kynurenine (KYN), an aryl hydrocarbon receptor ligand; subsequent catabolism of

Received 12 June 2017; editorial decision 27 August 2017; accepted 24 October 2017.

Presented in part: Was presented as an oral poster (poster no. A6850) at the American Thoracic Society Conference, Washington DC, May 19–24, 2017.

*See the full listing of the INSIGHT FLU003 Plus Study Group after the References.

Correspondence: S. L. Pett, FRACP, FRCPE, PhD, Medical Research Council Clinical Trials Unit (MRC CTU) at University College London, Aviation House, 125, Kingsway, London, WC2B 6NH, UK (s.pett@ucl.ac.uk or spett@kirby.unsw.edu.au).

Open Forum Infectious Diseases®

© The Author(s) 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

DOI: 10.1093/ofid/ofx228




Figure 1. L-tryptophan metabolic pathway.

KYN leads to a number of KYN pathway metabolites (Figure 1). IDO1, found in the placenta, gut, and T cells, appears to play an important role in immune tolerance. IDO activity is induced by the immunomodulatory cytokine interferon-gamma (IFN- γ ; which also appears to play an important role in mobilizing tryptophan into cells), other pro-inflammatory cytokines including interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF- α), amyloid peptides, and lipopolysaccharides. Increased IDO activity ultimately leads, via the production of KYN (the “L-Kynurenine shunt”), to T-cell apoptosis, reduced T-cell proliferation, and an anergic state, with increased immunosuppressant, T-regulatory cells [6, 7]. The exact pathways for the interaction between antigen-presenting cells and the suppression of T-cell activity via IDO is not completely understood.

Increased plasma KYN levels and KYN-to-TRP (KT) ratios (as a measure of IDO activity) have been found in patients with systemic inflammatory response syndrome, sepsis, and septic shock, but as yet, it is unclear what the findings mean [8]. Suzuki and colleagues [9] explored the correlation between KT ratio and clinical outcome in patients hospitalized with community-acquired pneumonia (CAP). In this group of patients, there was a significant positive correlation between both KYN levels and KT ratio with severity of CAP. Moreover, when these CAP

patients were divided into nonsepsis, sepsis, severe sepsis, and septic shock categories, there was a clear correlation between increasing sepsis severity and increasing levels of KYN, decreasing levels of TRP, and, as a result, increasing KT ratios indicative of IDO activation. Nonsurvivors also had significantly higher KT ratios than survivors [9].

To date, relatively little is known about the role of IDO in the human immune response to influenza, with most published data from murine influenza models. In the murine influenza model, influenza induced IDO activity in mouse lung tissue and draining lymph nodes [10]. Moreover, IDO knockout mice and mice treated with IDO inhibitors had better outcomes [11, 12].

In a multiplex biomarker analysis of patients enrolled with influenza A(H1N1)pdm09 virus in FLU003 Plus (see the Methods), Davey and colleagues [13] found several biomarkers that predicted poor clinical outcomes (defined as death, in-patient stay of >28 days, or intensive care unit [ICU] admission), including markers of macrophage activation/chemokines, T-cell activation, and acute phase reactants.

We therefore hypothesized that increased KT ratio would be associated with poor clinical outcomes (as defined by Davey and colleagues [13]) from influenza. In this analysis, we present novel data on the association of increased KT ratio and disease

progression and the association of KT ratio with the selected biomarkers identified by Davey and colleagues [13] and, additionally, interleukin-17 (IL-17) and interferon-gamma (IFN- γ), chosen specifically because of their role in regulating IDO activity.

METHODS

FLU003Plus is an ongoing, international observational study of adults hospitalized with influenza that began in 2009, following the emergence of the influenza A(H1N1)pdm09 virus [14]. Participants are eligible for enrollment in FLU003Plus if they have laboratory-confirmed influenza based on a local nucleic acid test (NAT) or influenza is suspected and a local NAT test has been performed. At enrollment, an upper respiratory tract swab is sent to a central laboratory for confirmation of influenza using polymerase chain reaction (PCR)-based NAT. FLU003Plus captures a wide range of clinical information, including the reasons for hospitalization, type of ward to which the patient was first admitted, and in subsequent visits at day 28 and day 60, clinical status including death. The primary end point of FLU003Plus is disease progression, defined as a composite of death, prolonged hospitalization >28 days, and postenrollment intensive care/mechanical ventilation/extracorporeal membrane oxygenation (ECMO) within 60 days of enrollment.

Ethics Statement

The FLU003Plus protocol and information statement and consent form were approved by both the local institutional ethics committees/review boards of the participant sites and the ethics committee of the sponsor of this study, the University of Minnesota. All participants or their representatives (when participants were unable to consent for themselves and where the ethics permission allowed for consent by a third party) provided written informed consent prior to their enrollment.

Study Design and Objectives

This was a matched case-control study. Cases were FLU003Plus patients with PCR-confirmed influenza A(H1N1)pdm09 virus with disease progression; controls had PCR-confirmed influenza A(H1N1)pdm09 virus and were matched on age (+/-4 years) and sex. Cases and controls were chosen from a subset of 209 FLU003Plus participants who were the focus of previous work on biomarkers [13]. Our primary objective was to explore the association of baseline (ie, the sample taken at the time of enrollment into FLU003Plus) KT ratio, as a marker of IDO activity, with disease progression. Key secondary objectives explored the association of baseline KT ratio with death, the multiplex panel of inflammatory biomarkers (as described by Davey et al. [13]), and baseline IFN- γ and IL-17. As described by Davey et al. [13], biomarkers were classified as belonging to 1 of 4 groups, that is, macrophage proinflammatory activation response, acute phase response, T-cell activation response, and macrophage chemokine response.

Laboratory Methods

Plasma Samples Preparation

Local labs at the sites stored plasma samples using the methodology described in the FLU003Plus laboratory manual. At study enrollment, blood was drawn into EDTA tubes and processed within 4 hours. All samples were centrifuged at room temperature at 1200 g \times 15 minutes, and the plasma aliquoted. These aliquots were then either stored immediately at -70/-80°C or initially at -20°C for a maximum of 4 days before being moved (on dry ice) into a -70/-80°C freezer. All samples used in this analysis had undergone 1 freeze-thaw cycle.

Mass Spectrometry Analysis

Sample Preparation

The method used is as described by Gulcev and colleagues [15]. Aliquots of 100 μ L plasma had a heavy standard of 3 μ L of 100 μ M of kynurenine D6 and 3 μ L of 1 mM tryptophan 13C11 (Cambridge Isotope Laboratories, Inc., Tewksbury, MA) added prior to any preparation. These aliquots were then mixed with 400 μ L of ice-cold solvent (100% methanol), vortexed, and placed on ice for 10 minutes. Samples were then centrifuged at 13000 \times g for 10 minutes at 4°C, and the supernatant was removed and transferred into a clean low-retention vial. This step was repeated once. Samples were concentrated using a vacuum centrifuge to ~50 μ L. Formic acid was used to acidify the plasma samples that were added to the starting buffer used in ultraperformance liquid chromatography (5% acetonitrile, 95% water, 0.1% formic acid) to 100 μ L.

Untargeted Mass Spectrometry Analysis

Undiluted sample (10 μ L) was injected into a Thermo Q-Exactive liquid chromatography-mass spectrometry (LC-MS; ThermoFisher Scientific, Marietta, OH) at 40°C. The samples were subjected to a gradient going from Buffer A to Buffer B over 15 minutes, then flushing for 5 minutes. Buffer A consisted of 99.9% water with 0.1% formic acid, while Buffer B was 99.9% acetonitrile with 0.1% formic acid.

XCMS Processing

The RAW files from the Q-exactive were converted into mzXML using MSconvert [16] and processed using XCMS online under the Q-Exactive parameters. The resulting file was used to extract intensities of a specific tryptophan and kynurenine metabolite's m/z and RT.

Liquid Chromatography-Tandem Mass Spectrometry Selective Reaction Monitoring Analysis of Tryptophan and Kynurenine

Diluted (1:1000 tryptophan and 1:100 for kynurenine) samples (20 μ L) were subjected to injection using an Agilent autosampler liquid chromatography-tandem mass spectrometry (LC-MS/MS) with an analytical Waters Symmetry C18, 3.5- μ m column connected to the 5500 iontrap (Sciex, Framingham, MA) fitted with a turbo V electrospray source. The samples were subjected

to a linear gradient of 2% acetonitrile, 0.1% formic acid to 98% acetonitrile 0.1% formic acid for 10 minutes at a column flow rate of 250 $\mu\text{L}/\text{min}$. Transitions monitored are in Table S1. The data were analyzed using MultiQuant (Applied Biosystems, Foster City, CA), which provided the peak area for the transitions. A standard curve was constructed using concentration ratios of heavy tryptophan/tryptophan and heavy kynurenine/kynurenine from femtomole to nanomole in 20 μL .

Measurement of IL-17 and IFN- γ

IL-17 and IFN- γ were measured using the Luminex platform at the University of Minnesota Cytokine Reference Laboratory (CLIA'88 licensed). Following the manufacturer's instructions, fluorescent magnetic beads (R&D Systems, Minneapolis, MN) coated with IL-17 and IFN- γ antibodies were added to each sample. After incubation and washing, biotinylated detection antibody was added, followed by phycoerythrin-conjugated streptavidin. The beads were read on a dual-laser fluidics-based

Luminex instrument (Bioplex 200) that determines the analyte being detected via color coding; the other measures the magnitude of the PE signal from the detection antibody, which is proportional to the amount of analyte bound to the bead. Samples were run in duplicate, and values were interpolated from 5-parameter fitted standard curves.

Measurement of Other Inflammatory Biomarkers

Other inflammatory markers (see Table 1) were previously published [13] and were used in this current analysis.

Statistical Methods

With 96 samples, power was 80% to detect a difference of 0.089 mM in KT ratios between cases and controls. Descriptive statistics were used to summarize the baseline characteristics. Spearman rank correlation coefficients were used to explore associations of baseline biomarkers with KT ratio. Conditional logistic regression was used to summarize the association of

Table 1. Clinical Characteristics, Kynurenine, Tryptophan, and KT Ratio, Multiplex Panel of Inflammatory Biomarkers of Cases and Controls Hospitalized With Influenza A(H1N1)pdm09

	Case (n = 32)	Control (n = 64)	P Value ^a
	No. (%) or Median (25th, 75th %)	No. (%) or Median (25th, 75th %)	
Female ^b	13 (41)	26 (41)	-
Age ^b	52 (41, 60)	53 (40, 60)	-
Nonwhite race	7 (22)	13 (20)	.84
Smoker	10 (36)	22 (34)	.86
Days since onset of influenza symptoms	8 (6, 10)	6 (4, 7)	.04
Asthma or chronic obstructive pulmonary disease	6 (19)	14 (22)	.70
Immune suppressive condition/treatment	8 (25)	7 (11)	.33
Cardiovascular or chronic liver/renal disease	8 (25)	11 (17)	.10
KYN μM	6.1 (3.9, 12.2)	3.9 (3.0, 5.9)	.003
TRP μM	32.4 (23.7, 40.7)	37.0 (27.1, 44.9)	.10
KT ratio	0.24 (0.13, 0.40)	0.12 (0.09, 0.17)	<.001
Macrophage proinflammatory activation response biomarkers			
IL-6, pg/mL	17.2 (12.9, 24.5)	10.7 (4.2, 19.0)	.01
TNA- α , pg/mL	14.4 (11.2, 18.4)	12.4 (10.3, 16.1)	.02
CD163, ng/mL	1608 (963, 2629)	710 (516, 1078)	<.001
sICAM-1, ng/mL	526 (294, 791)	237 (95.7, 404)	.002
IL-8, pg/mL	50.4 (26.0, 77.3)	23.5 (13.7, 44.7)	.004
Acute phase response biomarkers			
D-dimer, $\mu\text{g}/\text{mL}$	3.55 (1.4, 5.0)	1.04 (0.6, 1.7)	<.001
LBP, $\mu\text{g}/\text{mL}$	35.4 (14.1, 57.3)	18.2 (9.7, 45.0)	.07
sVCAM-1, ng/mL	715 (527, 970)	392 (177, 667)	.002
T-cell activation response biomarkers			
IL-2, pg/mL	3.67 (2.4, 7.9)	2.08 (1.2, 4.2)	.009
IL-10, pg/mL	26.7 (11.6, 95.5)	10.8 (6.7, 19.4)	.003
Macrophage chemokine response biomarkers			
MCP-1, pg/mL	1164 (539, 2440)	585 (379, 930)	.001
IP-10, pg/mL	3160 (919, 7308)	1068 (518, 2453)	.009

For biomarkers, values are \log_{10} transformed for significance testing.

Abbreviations: IL, interleukin; KT, kynurenine-to-tryptophan ratio; KYN, kynurenine; LBP, lipopolysaccharide-binding protein; TRP, tryptophan.

^aUnivariate conditional logistic.

^bMatching factor.

the baseline KT ratio at enrollment with disease progression. Odd ratios (ORs) for upper and middle vs lower tertiles of the KT ratios are provided with the 95% confidence intervals and *P* values. This analysis was repeated with adjustment for duration of symptoms at enrollment, with and without additional adjustment for log₁₀ transformed biomarkers IL-10, sVCAM1, IL-2, and MCP-1. These particular biomarkers were chosen as they represented the biomarkers most strongly related to disease progression in the categories of macrophage proinflammatory activation response, acute phase response, T-cell activation response, and macrophage chemokine response, respectively. *P* values were not adjusted for these multiple comparisons.

RESULTS

Thirty-two participants met our case definition; 22 of these died. Two controls were available for all cases. Cases had been symptomatic for a median of 8 days, whereas controls had been symptomatic for a median of 6 days (*P* = .04 for the difference) (Table 1). Median baseline KT ratios were 2-fold higher for cases (0.24 mM/M; 25th, 75th percentiles, 0.13, 0.40) than controls (0.12 mM/M; 25th, 75th percentiles, 0.09, 0.17; *P* ≤ .001). All 12 inflammatory biomarkers except lipopolysaccharide-binding protein were significantly elevated in cases compared with controls (Table 1). The correlation of KYN, TRP, and KT ratios with each of the 12 biomarkers is described in Table 2; all 12 of these biomarkers correlated with the KT ratio.

When KT ratios were divided into tertiles (Table 3), 60% of cases vs 20% of controls had a KT ratio in the highest tertile (0.21–0.84 mM/M), and 16% of cases vs 39% of controls had a

ratio in the lowest tertile (0.04–0.10 mM/M). Table 3 shows the unadjusted and adjusted (for duration of symptoms at the time of enrollment) conditional logistic analyses. The unadjusted odds ratio (cases vs controls) was 5.94 (95% CI, 1.7–20.3) for those in the highest tertile of KT ratio as compared with the lowest tertile. When adjusted for symptom duration alone, the OR for disease progression (ie, case vs control status) for those in the highest vs lowest KT ratio tertile was 9.94 (95% CI, 2.25–43.90; *P* ≤ .001). When restricted to the cases who died (*n* = 22), the OR for death (cases vs controls, and adjusted for symptom duration) for those in the highest vs lowest KT ratio tertile was 12.14 (95% CI, 1.69–87.25; *P* = .004; data not shown).

The analysis was repeated adjusting for duration of symptoms at enrollment and log₁₀ transformed biomarkers IL-10, sVCAM1, IL-2, and MCP-1. With this adjustment, the predictive value of the highest KT ratio tertile vs the lowest tertile for disease progression, was attenuated to 3.34 (95% CI, 0.55–20.33; *P* = .06; data not shown).

In addition, we explored the relationship of poor outcome with downstream metabolites of L-kynurenine (Figure 1). We found clear associations between poor outcomes and higher levels of downstream KYN metabolites that included kynurenic acid, anthranilic acid, 3-hydroxykynurenine, and quinolinic acid (Table 4). One downstream metabolite, glutaryl-CoA, was decreased in cases compared with controls.

IFN-γ and IL-17 were measured in cases and controls; 83% of the IFN-γ levels were below the lower detection limit (data not shown), and therefore we could not analyze relationships between IFN-γ and outcomes. IL-17 levels (Table 5) were categorized as below the lower detection limit, and approximate median levels in those with detectable results. Equivalent numbers of cases and controls had IL-17 levels below the detection limit at study enrollment.

DISCUSSION

Despite the relatively small cohort of patients studied, our data reveal a strong association between high KT ratio and poor clinical outcome in adults hospitalized with influenza.

The high levels of metabolites of the tryptophan metabolic pathway also strengthen the evidence for IDO activation in this setting. IDO is induced by pro-inflammatory cytokines such as TNF-α and IFN-γ following viral infection. In murine models, influenza induces IDO expression in lung tissue and lymph nodes [10, 11], and IDO inhibitors improve T-cell responses toward the virus [12]. Most of the effects of tryptophan catabolism come from accumulation of its active downstream metabolites, many of which modulate the inflammatory state. Kynurenic acid is a potent agonist of the orphan G-protein-coupled receptor GPR35, whose expression in T cells leads to an immunosuppressive phenotype [17]. In monocytes and macrophages, the interaction of GPR35 with kynurenic acid downregulates the pro-inflammatory effects of bacterial lipopolysaccharide

Table 2. Correlation of Baseline Biomarkers With KYN, TRP, and the KT Ratio

	KYN		TRP		KT Ratio	
	Coeff	<i>P</i> Value	Coeff	<i>P</i> Value	Coeff	<i>P</i> Value
Macrophage proinflammatory activation response biomarkers						
IL-6, pg/mL	0.44	<.001	−0.06	.55	0.40	<.001
TNA-α, pg/mL	0.53	<.001	−0.04	.69	0.47	<.001
CD163, ng/mL	0.51	<.001	−0.13	.20	0.50	<.001
sICAM-1, ng/mL	0.20	.05	−0.12	.25	0.26	.010
IL-8, pg/mL	0.62	<.001	−0.08	.45	0.55	<.001
Acute phase response biomarkers						
D-dimer, μg/mL	0.42	<.001	−0.09	.36	0.45	<.001
LBP, μg/mL	0.38	<.001	−0.05	.66	0.35	<.001
sVCAM-1, ng/mL	0.24	.02	−0.08	.44	0.28	.005
T-cell activation response biomarkers						
IL-2, pg/mL	0.54	<.001	−0.05	.64	0.49	<.001
IL-10, pg/mL	0.51	<.001	−0.13	.19	0.53	<.001
Macrophage chemokine response biomarkers						
MCP-1, pg/mL	0.56	<.001	−0.19	.06	0.58	<.001
IP-10, pg/mL	0.63	<.001	−0.08	.45	0.56	<.001

*P*Values are from a univariate conditional logistic model.

Abbreviations: IL, interleukin; KT, kynurenine-to-tryptophan ratio; KYN, kynurenine; LBP, lipopolysaccharide-binding protein; TRP, tryptophan.

Table 3. Odds Ratios for Tertiles of KYN, TRP, and KT Ratio

Tertiles	Case (n = 32)		Control (n = 64)		Unadjusted ^a		Adjusted ^a	
	No.	Pct.	No.	Pct.	OR ^a	95% CI	OR ^a	95% CI
Kynurenine, μM								
2.00–3.67	6	18.8	26	40.6	ref.		ref.	
3.68–5.89	9	28.1	23	35.9	1.55	0.51–4.70	2.61	0.64–7.28
5.90–33.9	17	53.1	15	23.4	4.25	1.39–12.98	5.95	1.60–22.08
<i>P</i> value, trend					.003		.005	
Tryptophan, μM								
9.7–28.3	13	40.6	19	29.7	2.46	0.80–7.58	3.73	1.07–13.01
28.4–41.0	12	37.5	20	31.3	2.10	0.70–6.27	3.11	0.90–10.67
41.1–62.1	7	21.9	25	39.1	ref.		ref.	
<i>P</i> value, trend					.10		.06	
KT ratio, mM/M								
0.04–0.10	5	15.6	25	39.1	ref.		ref.	
0.11–0.20	8	25.0	26	40.6	1.50	0.40–5.64	1.96	0.44–8.79
0.21–0.84	19	59.4	13	20.3	5.94	1.74–20.33	9.94	2.25–43.90
<i>P</i> value					<.001		<.001	

Abbreviations: KT, kynurenine-to-tryptophan ratio; KYN, kynurenine; OR, odds ratio; TRP, tryptophan.

^aConditional logistic. Adjusted model contains covariates for duration of symptoms at time of enrollment. *P* value shown is for lab result as a continuous variable.

[18–20]. Quinolinic acid is an end-product of L-kynurenine metabolism and is a known agonist to N-methyl-D-aspartate receptors in nerve cells. Quinolinic acid also generates

reactive oxygen species capable of inducing the secretion of potent chemokines and pro-inflammatory cytokines [21, 22]. The metabolite 3-hydroxykynurenine (3-HK) is a redox active

Table 4. Odds Ratios for Tertiles of KYN Metabolites

Tertiles (\log_{10})	Case (n = 32)		Control (n = 64)		Unadjusted ^a		Adjusted ^a	
	No.	Pct.	No.	Pct.	OR ^a	95% CI	OR ^a	95% CI
Kynurenic acid								
6.54–6.93	8	25.0	24	37.5	ref.		ref.	
6.93–7.13	9	28.1	23	35.9	1.01	0.29–3.46	0.88	0.24–3.17
7.14–8.99	15	46.9	17	26.6	2.86	0.94–8.70	2.34	0.72–7.62
<i>P</i> value, trend					.002		.004	
Anthranilic acid								
6.34–6.71	6	18.8	26	40.6	ref.		ref.	
6.72–6.90	9	28.1	23	35.9	1.84	0.52–6.44	1.88	0.50–7.00
6.91–7.72	17	53.1	15	23.4	5.45	1.52–19.44	5.59	1.43–21.84
<i>P</i> value, trend					<.001		.002	
3-hydroxykynurenine								
6.26–6.72	6	18.8	26	40.6	ref.		ref.	
6.73–7.09	8	25.0	24	37.5	1.10	0.32–3.78	1.49	0.38–5.90
7.10–8.25	18	56.3	14	21.9	3.98	1.39–11.36	5.18	1.54–17.42
<i>P</i> value, trend					.003		.003	
Quinolinic acid								
5.66–6.58	7	21.9	25	39.1	ref.		ref.	
6.59–6.92	7	21.9	25	39.1	1.09	0.31–3.92	1.59	0.38–6.60
6.93–8.32	18	56.3	14	21.9	4.01	1.28–12.54	5.21	1.42–19.10
<i>P</i> value, trend					.001		.001	
Glutaryl-CoA								
5.03–6.59	17	53.1	15	23.4	37.52	4.19–336.1	27.39	3.01–249.4
6.60–6.92	13	40.6	19	29.7	16.96	2.16–133.4	16.07	2.02–127.8
7.08–7.72	2	6.3	30	46.9	ref.		ref.	
<i>P</i> value, trend					.003		.009	

Abbreviations: KYN, kynurenine; OR, odds ratio.

^aConditional logistic. Adjusted model contains a covariate for duration of symptoms at time of enrollment. *P* value shown is for lab result as a continuous variable.

Table 5. Odds Ratios for Categories of Baseline IL-17 Levels

IL-17 Levels	Case (n = 32)		Control (n = 64)		Unadjusted ^a		Adjusted ^a	
	No.	Pct.	No.	Pct.	OR ^a	95% CI	OR ^a	95% CI
Undetectable	15	46.9	30	46.9	ref.		ref.	
0.16–0.59 pg/mL	6	18.8	18	28.1	0.61	0.18–2.06	0.33	0.08–1.33
0.60–15.5 pg/mL	11	34.4	16	25.0	1.30	0.49–3.43	0.98	0.34–2.78

Abbreviation: OR, odds ratio.

^aConditional logistic. Adjusted model contains covariate for duration of symptoms at time of enrollment.

compound that regulates the local oxidative status. In a pro-oxidative state, 3-HK demonstrates cellular toxicity [23].

Although the effect of downstream metabolites was diluted somewhat when we controlled for baseline levels of other cytokines, there was still a trend to significance for the highest KT ratio tertile compared with the lowest as a predictor of poor clinical outcome. It is important to note that we did not set out to show that KT ratio performed better than the multiplex panel of inflammatory cytokines/vascular markers. Rather, our aim in exploring this association was to try and understand the biological relationship between these inflammatory markers and the IDO pathway in this setting. Our data suggest that activation of the IDO pathway might contribute to poor outcomes, independent of other inflammatory pathways.

We were unable to quantify IFN- γ levels in the majority of patients in this subanalysis, which we suspect was due to a technical issue related to the samples utilized having already undergone 1 freeze-thaw cycle [24] and this cytokine being vulnerable to a freeze-thaw cycle in a way that assessment of amino acids and their metabolite measured using LC-MS/MS are not. Another reason for this may have been the prolonged interval from symptom onset to sampling or inadequate responses [25]. IL-17 appears to have a dual role both as a pro- and anti-inflammatory cytokine, especially when produced by regulatory T cells [26–29]. With respect to IL-17, there was no clear difference in the baseline levels between cases and controls, and as such, in this analysis at least, we have no evidence that IL-17 was contributing to the cytokine storm or, conversely, and reflecting its dual role, contributing to an immunosuppressive state.

In this analysis, we chose death and/or mechanical ventilation as the end points of interest, as both are clinically important, robust, and verifiable. While sites were required to report suspected/confirmed infections with other pathogens including bacteria, the study did not require the submission of supporting documentation. As such, we felt we could not verify these sepsis/bacterial infection events with sufficient certainty to include them as either an end point or covariate in the analysis. Our findings, however, may still represent the net effect of influenza plus secondary bacterial (and/or other pathogen) infections in both cases and controls, especially as they are similar to the findings revealed by other groups that have demonstrated a strong association between elevated IDO activity and poor

clinical outcomes in those with CAP +/- sepsis and septic shock [3, 9] or sepsis alone [30]. Moreover, in these other studies, IDO activity was predictive of mortality, unlike the respiratory rate or the C-reactive protein level [9]; in 1 study of sepsis, decreases in the median KT ratio over time correlated with decreases in the Sequential Organ Failure Assessment score, an objective assessment of improving clinical outcome [30]. While tryptophan deficiency alone can lead to cell dysfunction or death, most of the effects of tryptophan catabolism come from accumulation of its active downstream metabolites, such as kynurenine [31, 32], which inhibits the clonal expansion of CD4⁺ T cells, leading to increased tolerance and immunosuppression. Quinolinic acid, another downstream metabolite, in nanomolar concentrations, is metabolized to nicotinic acid mononucleotide and the nicotinamide adenine dinucleotide via a salvage pathway, but in high concentration, it is directly toxic to cells [22, 32].

It will be important to expand our understanding of the role of this immunoregulatory metabolic pathway in all types of influenza (and other concurrent infections) and the relative balance of immune activation vs immunosuppression. These data will help discern whether the many IDO inhibitors currently in development as adjunctive therapies for cancer may have potential clinical utility as therapeutic agents in severe influenza and/or other infections. However, clinicians considering the use of IDO inhibition in this setting should proceed with caution, as drugs inhibiting 1 part of an interlinked and complex metabolic pathway may have a detrimental effect via the upregulation of compensatory pro-inflammatory and/or immunosuppressive pathways.

Conclusion and Future Directions

In summary, in this small case-control study, we have shown that adults hospitalized with influenza A(H1N1)pdm09 and high KT ratio have greater odds of progression to death or mechanical ventilation. Measurement of this biomarker can be performed on plasma or serum, utilizing a standard tandem mass spectrometry approach available in most analytical laboratories; moreover, the assay is robust and reproducible across different laboratories. While this initial study reveals IDO activity as a putative biomarker to identify those at risk of deterioration, our findings need to be confirmed in further studies of all types/subtypes of influenza, preferably with longitudinal

sampling, in which clinical outcomes are rigorously captured. Lastly, future studies in which peripheral blood mononuclear cells are collected and isolated would potentially identify the cellular production of IDO and give insight into the relationship of this metabolic pathway with the innate immune response.

Supplementary Data

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

We extend our grateful thanks to all the volunteers who have been participating in this study.

Financial support. The INSIGHT FLU studies are funded under a Subcontract award 13XS134 under Leidos Biomed's Prime Contract HHSN261200800001E and HHSN261201500003I, NCI/NIAID.

Potential conflicts of interest. The views expressed in this article are those of the authors and do not reflect the views of the US Government, the National Institutes of Health, the Department of Veterans Affairs, the funders, or any of the authors' affiliated academic institutions. Sarah L. Pett: grants from the University of Minnesota to support the conduct of the trial at the FLU003Plus sites under the jurisdiction of the University of New South Wales; funding from the University of New South Wales to conduct the FLU003Plus trial at the clinical site. Ken Kunisaki: protected research time was provided by the Department of Veterans Affairs Office of Research and Development. Deborah Wentworth: none. Timothy Griffin: none. Ioannis Kalomenidis: none. Raquel Nahra: none. Rocio Montejano Sanchez: none. Shane Hodgson: none. Kiat Ruxrungtham: protected research time was provided by the Department of Medicine, The Faculty of Medicine, Chulalongkorn University, Thailand. Chris Wendt: protected research time was provided by the Department of Veterans Affairs Office of Research and Development. Dominic Dwyer: funding from the University of New South Wales to support the conduct of the FLU003Plus clinical trial at the clinical site. Richard Davey: funding from the University of Minnesota to support the conduct of the FLU003Plus clinical trial at the clinical site. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Yeung AW, Terentis AC, King NJ, Thomas SR. Role of indoleamine 2,3-dioxygenase in health and disease. *Clin Sci (Lond)* **2015**; 129:601–72.
2. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. *Nat Rev Immunol* **2007**; 7:875–88.
3. Schmidt SV, Schultze JL. New insights into IDO biology in bacterial and viral infections. *Front Immunol* **2014**; 5:384.
4. Gostner JM, Becker K, Überall F, Fuchs D. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment. *Expert Opin Ther Targets* **2015**; 19:605–15.
5. Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. *Trends Pharmacol Sci* **2013**; 34:136–43.
6. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. *J Immunol* **2006**; 176:6752–61.
7. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF- κ B activation. *Nat Rev Immunol* **2007**; 7:817–23.
8. Changsirivathanathamrong D, Wang Y, Rajbhandari D, et al. Tryptophan metabolism to kynurenine is a potential novel contributor to hypotension in human sepsis. *Crit Care Med* **2011**; 39:2678–83.
9. Suzuki Y, Suda T, Yokomura K, et al. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia. *J Infect* **2011**; 63:215–22.
10. Yoshida R, Urade Y, Tokuda M, Hayaishi O. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. *Proc Natl Acad Sci U S A* **1979**; 76:4084–6.

11. Huang L, Li L, Klonowski KD, et al. Induction and role of indoleamine 2,3-dioxygenase in mouse models of influenza A virus infection. *PLoS One* **2013**; 8:e66546.
12. Fox JM, Sage LK, Huang L, et al. Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. *J Gen Virol* **2013**; 94:1451–61.
13. Davey RT Jr, Lynfield R, Dwyer DE, et al; INSIGHT FLU 002 & 003 Study Groups. The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. *PLoS One* **2013**; 8:e57121.
14. <https://clinicaltrials.gov/ClinicalTrials.gov>. Identifier: NCT01056185.
15. Gulcević M, Reilly C, Griffin TJ, et al. Tryptophan catabolism in acute exacerbations of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* **2016**; 11:2435–46.
16. <http://proteowizard.sourceforge.net/tools.shtml>. Accessed 1 April 2017.
17. Sage LK, Fox JM, Mellor AL, et al. Indoleamine 2,3-dioxygenase (IDO) activity during the primary immune response to influenza infection modifies the memory T cell response to influenza challenge. *Viral Immunol* **2014**; 27:112–23.
18. Wang J, Simonavicius N, Wu X, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. *J Biol Chem* **2006**; 281:22021–8.
19. Barth MC, Ahluwalia N, Anderson TJ, et al. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. *J Biol Chem* **2009**; 284:19189–95.
20. Tiszlavicz Z, Németh B, Fülöp F, et al. Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor- α (TNF- α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. *Naunyn Schmiedebergs Arch Pharmacol* **2011**; 383:447–55.
21. Guillemin GJ, Croitoru-Lamoury J, Dormont D, et al. Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. *Glia* **2003**; 41:371–81.
22. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. *FEBS J* **2012**; 279:1356–65.
23. Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. *J Neurochem* **1998**; 70:299–307.
24. Yin P, Peter A, Franken H, et al. Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. *Clin Chem* **2013**; 59:833–45.
25. Lee N, Wong CK, Chan PK, et al. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. *Clin Infect Dis* **2007**; 45:723–31.
26. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. *Immunology* **2010**; 129:311–21.
27. Astry B, Venkatesha SH, Moudgil KD. Involvement of the IL-23/IL-17 axis and the Th17/Treg balance in the pathogenesis and control of autoimmune arthritis. *Cytokine* **2015**; 74:54–61.
28. Voo KS, Wang YH, Santori FR, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. *Proc Natl Acad Sci U S A* **2009**; 106:4793–8.
29. Mercer F, Khaïtan A, Kozhaya L, et al. Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. *J Immunol* **2014**; 193:1047–54.
30. Darcy CJ, Davis JS, Woodberry T, et al. An observational cohort study of the kynurenine to tryptophan ratio in sepsis: association with impaired immune and microvascular function. *PLoS One* **2011**; 6:e21185.
31. Takikawa O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. *Biochem Biophys Res Commun* **2005**; 338:12–9.
32. Palego L, Betti L, Rossi A, Giannaccini G. Tryptophan biochemistry: structural, nutritional, metabolic, and medical aspects in humans. *J Amino Acids* **2016**; 2016:8952520.

The INSIGHT FLU003 Plus Study Group.

International coordinating centers: Copenhagen: J. Lundgren, P. Jansson, M. Pearson, B. Aagaard; London: F. Hudson, R. Bennet, F. Pacciarini, B. Angus, N. Paton, Y. Collaco Moraes; Sydney: D. Cooper, S. Pett, S. Emery, D. Courtney-Rogers, R. Robson; Washington: F. Gordin, A. Sanchez, B. Standridge, M. Vjecha. Site coordinating centers: Argentina: A. Moricz, M. Delfino, W. Belloso, M. Losso; Germany: K. Tillmann; Greece: G. Touloumi, V. Gioukari, O. Anagnostou; Peru: A. La Rosa, M. J. Saenz; Spain: P. Lopez, P. Herrero, B. Portas; Thailand: A. Avihingsanon, K. Ruxrungtham, P. Kaewon, S. Ubolyam. Statistical and Data Management Center: K. Brekke, M. Campbell, E. Denning, A. DuChene, N. Engen, M. George, M. Harrison, J. D. Neaton, R. Nelson, S. F. Quan, T. Schultz, D. Wentworth. Specimen repositories and laboratories: J. Baxter, S. Brown

(Leidos Biomedical Research, Inc.); M. Hoover (ABML). National Institute of Allergy and Infectious Disease/Leidos: J. Beigel, R. T. Davey Jr., R. Dewar, E. Gover, R. McConnell, J. Metcalf, V. Natarajan, T. Rehman, J. Voell. Centre for Infectious Diseases and Microbiology Laboratory Services (Westmead Hospital and University of Sydney, Westmead, New South Wales, Australia): D. E. Dwyer, J. Kok. Centers for Disease Control and Prevention: T. Uyeki. Community Representative: D. Munroe. Clinical site investigators: United States (n = 484); Baystate Infectious Diseases Clinical Research (n = 99): A. Paez, M. Bertrand; Mayo Clinic (n = 69): Z. Temesgen, S. Rizza; Duke University (n = 45): C. Wolfe, J. Carbonneau; University of Illinois at Chicago (n = 39): R. Novak, M. Schwarber; Miami Valley Hospital (n = 32): H. Polenakovic, L. Clark; Brigham and Women's Hospital (n = 30): N. Patil; Montefiore Medical Center (n = 26): P. Riska, J. Omotosho; Henry Ford Health System (n = 25): L. Faber, N. Markowitz; Weill Cornell Medical College (n = 25): M. Glesby, K. Ham; George Washington Medical Faculty Associates (n = 23): D. Parenti, G. Simon; Cooper University Hospital (n = 13): J. Baxter, P. Coburn; University of Pittsburgh Medical Center (n = 12): M. Freiberg, G. Koerbel; NJMS Adult Clinical Research Center (n = 10): N. Dharan, M. Paez-Quinde; University of Tennessee College of Medicine (n = 9): J. Gunter; Medical College of Wisconsin (n = 7): M. Beilke, Z. Lu; Minneapolis Medical Research Foundation, Hennepin County Medical Center (n = 4): E. Gunderson, J. Baker; The Ohio State University Medical Center (n = 4): S. Koletar, H. Harber; UNC AIDS Clinical Trials Unit (n = 3): C. Hurt, C. Marcus; Washington DC VA Medical Center (n = 3): M. Allen, S. Cummins; David Geffen School of Medicine at UCLA (n = 2): D. Uslan, T. Bonam; Community Research Initiative - Springfield (n = 1): A. Paez, F. Santiago; Denver Public Health (n = 1): D. States, E. Gardner; SUNY Downstate Medical Center (n = 1): J. DeHovitz, S. Holman; Virginia Commonwealth University (n = 1): V. Watson, D. Nixon; Australia (n = 338); Westmead Hospital (n = 287): D. Dwyer, M. Kabir; St. Vincent's Hospital (n = 26): S. Pett, F. Kilkenny; The Alfred Hospital (n = 22): J. Elliott, J. Garlick; Cairns Sexual Health Service (n = 3): J. McBride, S. Richmond; Argentina (n = 216); Hospital Italiano de Buenos Aires (n = 92): L. Barcan, M. Sanchez; Hospital Profesor Bernardo Houssay (n = 49): G. Lopardo, L. Barcelona; CEMIC (n = 37): P. Bonvehi, E. R. Temporiti; Hospital General de Agudos J. M. Ramos Mejia (n = 34): M. Lasso, L. Macias; Hospital Nacional Profesor Alejandro Posadas (n = 3): H. Laplume, L. Daciuk; Hospital Interzonal General de Agudos Dr. Diego Paroissien (n = 1): E. Warley, S. Tavella; Spain (n = 195); Hospital General Universitario Gregorio Marañón (n = 61): E. Fernandez Cruz; Hospital Universitario La Paz (n = 37): J. Paño; Hospital Clínico San Carlos (n = 25):

V. Estrada; Hospital Universitario de Álava (n = 22): P. Lopetegui; Hospital Universitario Infanta Leonor (n = 20): T. Gimenez Julvez, P. Ryan; Hospital Universitario Príncipe de Asturias (n = 13): J. Sanz Moreno; Hospital del Mar (n = 10): H. Knobel; Hospital Carlos III (n = 5): V. Soriano; Hospital Universitari Mutua Terrassa (n = 2): D. Dalmau; United Kingdom (n = 186); Sheffield Teaching Hospitals (n = 76): D. Dockrell; Churchill Hospital (n = 43): B. Angus; Newcastle Hospitals (n = 40): D. Price; Royal Sussex County Hospital (n = 23): M. Newport; The James Cook University Hospital (n = 4): D. Chadwick; Denmark (n = 181); Aarhus Universitetshospital, Skejby (n = 88): L. Østergaard, Y. Yehdego; Odense University Hospital (n = 37): C. Pedersen, L. Hergens; CHIP, Rigshospitalet, Department of Infectious Diseases, Section 2100 (n = 26): Z. Joensen, B. Aagaard; Hvidovre University Hospital, Department of Infectious Diseases (n = 14): G. Kronborg, P. Collins; Aalborg Hospital (n = 12): H. Nielsen; Rigshospitalet, Infektionsmedicinsk Ambulatorium 8622 (n = 4): J. Gerstoft, B. Baadegaard; Greece (n = 161); 1st Respiratory Medicine Dept, Athens Hospital for Diseases of the Chest, Sotiria Hospital (n = 89): N. Koulouris; Attikon University General Hospital (n = 44): A. Antoniadou, K. Protopappas; 3rd Pulmonary Dept and 2nd Internal Medicine Dept, Sismanoglio Athens General Hospital (n = 13): V. Polixronopoulos, F. Diamantea; Hippokraton University General Hospital of Athens (n = 12): H. Sambatakou, I. Mariolis; 12th Respiratory and TB Medical Dept, Athens Hospital for Diseases of the Chest, Sotiria Hospital (n = 3): N. Vassilopoulos, A. Gerogiannis; Peru (n = 133); Hospital Nacional Arzobispo Loayza (n = 105): Y. Pinedo Ramirez, E. Cornelio Mauricio; Hospital Nacional Guillermo Almenara Irigoyen (n = 28): J. Vega Bazalar, R. Castillo Cordova; Germany (n = 112); Uniklinik Köln (n = 57): G. Fätkenhuerer, E. Thomas; Charité Universitätsklinikum Berlin (n = 15): F. Bergmann, U. Föllmer; Universitätsklinikum Bonn (n = 15): J. Rockstroh, A. Englehardt; Universitätsklinikum Frankfurt (n = 11): C. Stephan, E. Thomas; Klinikum der Universität München (n = 7): J. Bogner; Klinikum der Ruhr-Universität Bochum (n = 4): N. Brockmeyer; Universitätsklinikum Würzburg (n = 3): H. Klinker; Thailand (n = 61); Khon Kaen University, Srinagarind Hospital (n = 43): P. Chetchotisakd, T. Jumpimai; Chulalongkorn University and the HIV-NAT (n = 18): A. Avihingsanon, K. Ruxrungtham; Belgium (n = 56); Centre Hospitalier Universitaire St. Pierre: N. Clumeck, K. Kameya; China (n = 24); Queen Elizabeth Hospital: M. Y. Chu, T. C. Wu; Poland (n = 14); Wojewodzki Szpital Zakazny: A. Horban, E. Bakowska; Austria (n = 11); University Vienna General Hospital: H. Burgmann, S. Tobudic; Norway (n = 9); Oslo University Hospital, Ullevål: A. Maagaard; Chile (n = 2); Fundación Arriarán: M. Wolff, G. Allendes.